HealthcareServices

Pompe Disease Industry Growth Insights: Revenue Forecast to 2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pompe disease market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Pompe Disease Market between 2026 and 2030?

The pompe disease market has experienced robust expansion in recent years. Its valuation is predicted to rise from $1.8 billion in 2025 to $1.91 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.2%. The historical increase can be attributed to several factors such as advancements in newborn screening programs, the introduction of approved ERT treatments, a greater understanding of rare genetic disorders, the broadening of genetic testing capabilities, and the establishment of more specialty care centers.

The pompe disease market size is projected to experience substantial growth over the coming years. It is anticipated to expand to $2.49 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. This expansion during the forecast period is fueled by escalating investments in gene and cell therapies, intensified research into next-generation ERTs, the widening application of personalized medicine approaches, improved access to rare disease diagnostics, and a heightened focus on early intervention strategies. Prominent trends expected in the forecast period include the increasing uptake of enzyme replacement therapy, a greater emphasis on early genetic screening, the evolving development of gene therapy approaches, the growth of specialized treatment centers, and improved long-term disease management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11906&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Pompe Disease Market?

Rising healthcare expenditure is projected to boost the Pompe disease market moving forward. This expenditure encompasses financial resources directed by governments, insurers, and private organizations toward enhancing medical services, strengthening diagnostic capabilities, and expanding treatment access. The need for greater healthcare investment is growing as health systems prioritize early detection, management of rare diseases, and improved patient outcomes. Such increased spending supports the broader adoption of enzyme replacement therapies and novel innovations, providing superior care and an improved quality of life for individuals with Pompe disease. For instance, a report from the UK-based government department, the Office for National Statistics, indicated in May 2023 that healthcare spending in the UK escalated by 5.6% between 2022 and 2023, a notable increase compared to the 0.9% growth in 2022. The UK’s healthcare expenditure amounted to around $317.63 billion (£292 billion) in 2023. Thus, the expansion in healthcare expenditure is expected to propel the Pompe disease market.

How Is The Pompe Disease Market Organized Into Various Segments?

The pompe disease market covered in this report is segmented –

1) By Type: Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Other Types

2) By Diagnosis: Blood Test, Genetic Test, Prenatal Test, Other Diagnosis

3) By Route Of Administration: Intravenous Administration, Parenteral, Other Routes Of Administrations

4) By Therapy Type: Enzyme Replacement Therapy (ERT), Pharmacological Chaperone Therapy, Gene Therapy, Other Therapies

5) By End Users: Hospitals Or Clinics, Specialty Metabolic Treatment Centers, Researchers, Other End-Users

Subsegments:

1) By Classic Infantile Form: Early-Onset Classic Pompe Disease, Severe Classic Pompe Disease

2) By Non-Classic Infantile Form: Mild Non-Classic Infantile Pompe Disease, Variants of Non-Classic Infantile Form

3) By Late-Onset Form: Adult-Onset Pompe Disease, Juvenile-Onset Pompe Disease

4) By Other Types: Pre-Symptomatic Pompe Patients, Other Rare Variants of Pompe Disease

What Trends Are Driving The Growth Trajectory Of The Pompe Disease Market?

Leading companies in the Pompe disease market are concentrating on forming strategic partnerships to bolster product innovation, extend their market presence, and enhance animal health solutions. A strategic partnership typically denotes a cooperative arrangement between two or more organizations, where they integrate their resources, expertise, and efforts to achieve mutual goals. For example, in June 2024, Shionogi & Company, Limited, a Japanese pharmaceutical firm, finalized a global licensing agreement with Maze Therapeutics, a US-based biotechnology company, for MZE001, an experimental oral drug aimed at Pompe disease. Shionogi obtained exclusive rights to MZE001 and its related intellectual property for an upfront payment of $150 million, in addition to potential milestone and royalty payments. This agreement was concluded after undergoing the necessary 30-day review period under U.S. antitrust law (HSR Act).

Who Are The Top-Performing Companies In The Pompe Disease Market In Recent Years?

Major companies operating in the pompe disease market are Sanofi S.A., Genzyme Corporation, Amicus Therapeutics Inc., BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Valerion Therapeutics LLC, Protalix BioTherapeutics, AVROBIO Inc., Abeona Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Audentes Therapeutics Inc., Genethon, Akashi Therapeutics, M6P Therapeutics, Aro Biotherapeutics Company, Avidity Biosciences Inc., Maze Therapeutics Inc., Novartis AG, F. Hoffmann-La Roche AG, Spark Therapeutics Inc., REGENXBIO Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report

Which Region Currently Holds The Largest Share Of The Pompe Disease Market?

North America was the largest region in the pompe disease market in 2025. The regions covered in the pompe disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pompe Disease Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11906&type=smp

Browse Through More Reports Similar to the Global Pompe Disease Market 2026, By The Business Research Company

Primary Care Poc Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/primary-care-poc-diagnostics-global-market-report

Gestational Trophoblastic Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/gestational-trophoblastic-disease-global-market-report

Poc Medical Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/poc-medical-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795